Xin Pan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xin Pan has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Anandi V Law
Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA, USA
1 shared publicationAnandi V. Law
Thomas Jefferson University
1 shared publication- Anandi V. Law
College of Pharmacy, Western University of Health Sciences, Pomona, CA 91766, USA
1 shared publication - Anandi V. Law
Assistant Professor, University of California, Irvine (UCI), School of Pharmacy and Pharmaceutical Sciences, Irvine, CA; Dean and Professor, Thomas Jefferson University, College of Pharmacy, Philadelphia, PA
1 shared publication - Andrea C. Wooley
Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL 62025, USA
1 shared publication Bertram Pitt
Department of Internal Medicine, Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, MI, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Healthcare utilization outcomes of clinical pharmacist-led clinics and remote patient monitoring: Real-world evidence
Objective: Remote patient monitoring (RPM) enables real-time data collection, improves care efficiency, and facilitates early detection of disease deterioration, yet evidence of its real-world impact in pharmacist-led clinics is limited. This study evaluated the impact of pharmacist-led care and the association between RPM plus clinical pharmacist-led care and healthcare utilization in outpatient clinics using real-world data. Methods: This retrospective cohort study analyzed patient registry data (2015-2023) from a managed care organization located in Palm Springs, California. Adults enrolled ≥6 months in pharmacist-run clinics were included. Patients were categorized into three device cohorts: glucometers, blood pressure (BP) monitors, and inhaler sensors. Each cohort was divided into (1) an intervention group receiving pharmacist care with RPM devices and (2) a standard care (SC) group receiving pharmacist care alone. Disease-specific healthcare utilization (hospitalizations, skilled nursing facility stays, emergency room visits) was assessed 6-month pre- and post-enrollment using generalized estimating equation models adjusting for baseline characteristics and reported as relative risks (RR) with 95% confidence intervals (CI). Results: A total of 4,348 patients were included: glucometer cohort (n=1,669; SC=989, RPM=680), BP monitor cohort (n=1,083; SC=970, RPM=113), and inhaler sensor cohort (n=1,596; SC=1,487, RPM=109). Healthcare utilization significantly decreased from pre- to post-enrollment by 47% in the glucometer cohort (RR 0.53; 95% CI, 0.37-0.77), 56% in the BP monitor cohort (RR 0.44; 95% CI, 0.33-0.58), and 60% in the inhaler sensor cohort (RR 0.40; 95% CI, 0.32-0.49). Integrating RPM glucometers was associated with a 50% reduction in utilization (RR 0.50; 95% CI, 0.30-0.84) compared with SC. In contrast, adding BP monitors or inhaler sensors did not significantly reduce utilization. Conclusions: Clinical pharmacist-led, RPM-enhanced care models were associated with reduced healthcare utilization among patients with chronic diseases. Future studies should explore the impact of RPM across diverse settings using randomized controlled designs to better isolate their effects.
- 1 February 2026
- Published by SAGE Publications in Digital Health
- Vol. 12
Open AccessHealthcare utilization outcomes of clinical pharmacist-led clinics and remote patient monitoring: Real-world evidence
Objective: Remote patient monitoring (RPM) enables real-time data collection, improves care efficiency, and facilitates early detection of disease deterioration, yet evidence of its real-world impact in pharmacist-led clinics is limited. This study evaluated the impact of pharmacist-led care and the association between RPM plus clinical pharmacist-led care and healthcare utilization in outpatient clinics using real-world data. Methods: This retrospective cohort study analyzed patient registry data (2015-2023) from a managed care organization located in Palm Springs, California. Adults enrolled ≥6 months in pharmacist-run clinics were included. Patients were categorized into three device cohorts: glucometers, blood pressure (BP) monitors, and inhaler sensors. Each cohort was divided into (1) an intervention group receiving pharmacist care with RPM devices and (2) a standard care (SC) group receiving pharmacist care alone. Disease-specific healthcare utilization (hospitalizations, skilled nursing facility stays, emergency room visits) was assessed 6-month pre- and post-enrollment using generalized estimating equation models adjusting for baseline characteristics and reported as relative risks (RR) with 95% confidence intervals (CI). Results: A total of 4,348 patients were included: glucometer cohort (n=1,669; SC=989, RPM=680), BP monitor cohort (n=1,083; SC=970, RPM=113), and inhaler sensor cohort (n=1,596; SC=1,487, RPM=109). Healthcare utilization significantly decreased from pre- to post-enrollment by 47% in the glucometer cohort (RR 0.53; 95% CI, 0.37-0.77), 56% in the BP monitor cohort (RR 0.44; 95% CI, 0.33-0.58), and 60% in the inhaler sensor cohort (RR 0.40; 95% CI, 0.32-0.49). Integrating RPM glucometers was associated with a 50% reduction in utilization (RR 0.50; 95% CI, 0.30-0.84) compared with SC. In contrast, adding BP monitors or inhaler sensors did not significantly reduce utilization. Conclusions: Clinical pharmacist-led, RPM-enhanced care models were associated with reduced healthcare utilization among patients with chronic diseases. Future studies should explore the impact of RPM across diverse settings using randomized controlled designs to better isolate their effects.
- Open Access
- 23 May 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (11) , 1227
The Comprehension, Cosmetics, Convenience, Content, and Credibility of Infographic Patient Information Leaflets (iPILs) Compared to Existing PILs (ePILs)
Background/Objectives: Existing patient information leaflets (ePILs), mandated by the FDA to accompany new prescriptions, are difficult to read and understand due to their complexity and poor visual design, especially for populations with low health literacy and low English proficiency. In this study, we developed infographic-based PILs (iPILs) with a concise question-and-answer format, emphasizing essential information, as specified by the FDA. This study compared iPILs and ePILs using the 5C factors: comprehension, cosmetics, convenience, content, and credibility, as perceived by English-speaking and Spanish-speaking populations. Methods: This multicenter, experimental survey study assessed the 5C factors. English and Spanish-speaking adults on ≥1 chronic medication were recruited from community pharmacies in California (CA) and Illinois (IL). They were stratified to review either an ePIL or an iPIL for one of four common medications. They completed a Medication Knowledge Quiz (MKQ) to show their comprehension using six open-ended questions. Subsequently, they received both PIL versions and answered preference questions about the 4C and media format and, lastly, about demographic and health literacy questions. Results: A total of 235 participants completed the surveys at three sites (CA-English, CA-Spanish, and IL-English), with differing participant characteristics. The CA-Spanish participants scored the lowest on health literacy and the number of health conditions. The MKQ scores for those using the iPILs were significantly higher than for those using the ePILs across all groups. They significantly correlated with health literacy results for the ePILs (r = 0.394, p < 0.001). The participants preferred the iPILs over the ePILs for four of the C factors, barring one content question. Regardless of age, printed formats were preferred (64.7%)—alone or with digital formats (21.3%)—over digital formats alone (3.4%). Overall, 79.1% of the participants preferred iPILs, 11.9% preferred ePILs, and 8.9% preferred either version. Conclusions: The infographic-based patient information leaflets (iPILs) were easier to read, navigate, and understand, making them more accessible to individuals with varying levels of health literacy. Infographic-based leaflets outperformed existing ones in user comprehension and were preferred due to their simple layout, ease of navigation, and helpfulness.
- 23 May 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (11) , 1227
Open AccessThe Comprehension, Cosmetics, Convenience, Content, and Credibility of Infographic Patient Information Leaflets (iPILs) Compared to Existing PILs (ePILs)
Background/Objectives: Existing patient information leaflets (ePILs), mandated by the FDA to accompany new prescriptions, are difficult to read and understand due to their complexity and poor visual design, especially for populations with low health literacy and low English proficiency. In this study, we developed infographic-based PILs (iPILs) with a concise question-and-answer format, emphasizing essential information, as specified by the FDA. This study compared iPILs and ePILs using the 5C factors: comprehension, cosmetics, convenience, content, and credibility, as perceived by English-speaking and Spanish-speaking populations. Methods: This multicenter, experimental survey study assessed the 5C factors. English and Spanish-speaking adults on ≥1 chronic medication were recruited from community pharmacies in California (CA) and Illinois (IL). They were stratified to review either an ePIL or an iPIL for one of four common medications. They completed a Medication Knowledge Quiz (MKQ) to show their comprehension using six open-ended questions. Subsequently, they received both PIL versions and answered preference questions about the 4C and media format and, lastly, about demographic and health literacy questions. Results: A total of 235 participants completed the surveys at three sites (CA-English, CA-Spanish, and IL-English), with differing participant characteristics. The CA-Spanish participants scored the lowest on health literacy and the number of health conditions. The MKQ scores for those using the iPILs were significantly higher than for those using the ePILs across all groups. They significantly correlated with health literacy results for the ePILs (r = 0.394, p < 0.001). The participants preferred the iPILs over the ePILs for four of the C factors, barring one content question. Regardless of age, printed formats were preferred (64.7%)—alone or with digital formats (21.3%)—over digital formats alone (3.4%). Overall, 79.1% of the participants preferred iPILs, 11.9% preferred ePILs, and 8.9% preferred either version. Conclusions: The infographic-based patient information leaflets (iPILs) were easier to read, navigate, and understand, making them more accessible to individuals with varying levels of health literacy. Infographic-based leaflets outperformed existing ones in user comprehension and were preferred due to their simple layout, ease of navigation, and helpfulness.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 12
Examining Symptom Management and Quality of Life of Loop Diuretic-Induced Overactive Bladder Among Heart Failure Patients: Physician and Patient Perspectives
Loop diuretics are strongly recommended in patients with chronic congestive heart failure (HF) to alleviate signs and symptoms of fluid overload. Loop diuretics help relieve congestive symptoms and reduce mortality, but may have side effects. This survey study examined the impact of loop diuretic-induced overactive bladder (LD-OAB) symptoms on quality of life (QOL) in HF patients; and management of OAB by HF patients and physicians. We found that (1) HF patients noted less severity of symptoms but similar QOL with non-HF. (2) HF patients (58.8%) self-managed and underreported symptoms to physicians compared to non-HF (74.8%); accordingly 65% of physicians noticed and managed symptoms. (3) Patients used mechanical solutions (pads/diapers, Kegel exercises, and fluid reduction), and physicians adjusted diuretic doses or prescribed medications for OAB. Our study highlighted that HF patients' QOL associated with bladder symptoms was not better than the non-HF group despite milder symptoms. Many HF patients either did not report or coped with/self-managed their loop diuretic-induced bladder symptoms, pointing to a need for better awareness of patient experiences and patient-physician communication.
- 1 January 2025
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 12
Open AccessExamining Symptom Management and Quality of Life of Loop Diuretic-Induced Overactive Bladder Among Heart Failure Patients: Physician and Patient Perspectives
Loop diuretics are strongly recommended in patients with chronic congestive heart failure (HF) to alleviate signs and symptoms of fluid overload. Loop diuretics help relieve congestive symptoms and reduce mortality, but may have side effects. This survey study examined the impact of loop diuretic-induced overactive bladder (LD-OAB) symptoms on quality of life (QOL) in HF patients; and management of OAB by HF patients and physicians. We found that (1) HF patients noted less severity of symptoms but similar QOL with non-HF. (2) HF patients (58.8%) self-managed and underreported symptoms to physicians compared to non-HF (74.8%); accordingly 65% of physicians noticed and managed symptoms. (3) Patients used mechanical solutions (pads/diapers, Kegel exercises, and fluid reduction), and physicians adjusted diuretic doses or prescribed medications for OAB. Our study highlighted that HF patients' QOL associated with bladder symptoms was not better than the non-HF group despite milder symptoms. Many HF patients either did not report or coped with/self-managed their loop diuretic-induced bladder symptoms, pointing to a need for better awareness of patient experiences and patient-physician communication.
- Open Access
- 9 February 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 812654
Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure
Background: This study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).Methods: This was a prospective cohort study. Three hundred and thirty-one consecutively enrolled AHF patients from March 2018 to November 2019 were divided into 3 subgroups according to sST2 levels: T1 (1.15–7.70 ng/ml; N = 110), T2 (7.71–17.24 ng/ml; N = 111), and T3 (17.26–47.42 ng/ml; N = 110). The patients were followed up for a median period of 21.0 months for the development of the primary endpoint. Cox proportional hazards model was performed to evaluate the prognostic value of sST2 for the clinical outcomes.Results: The mean age of patients was 69 years (range, 34–93 years), and 70.4% were male. During the follow-up period, 63 participants died. Patients with higher sST2 levels had lower left ventricular ejection fraction (correlation = −0.119, P = 0.031), and higher New York Heart Association classification (correlation = 0.443, P < 0.001) and N-terminal pro-B type natriuretic peptide (NT-proBNP) levels (correlation = 0.392, P < 0.001). Higher sST2 was also associated with creatinine, urea nitrogen, hemoglobin, and left ventricular mass index. Multivariate analysis revealed that sST2 (per log unit, hazard ratio: 2.174, 95% confidence interval [CI] 1.012–4.67, P = 0.047) and NT-proBNP (per log unit, HR 2.171, 95%CI 1.169–4.032, P < 0.001) were independent risk factors for the primary outcome in all patients with AHF.Conclusion: sST2 can provide prognostic information in AHF. The higher the sST2 level in patients with AHF, the higher the incidence of cardiovascular death.
- 9 February 2022
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 9, 812654
Open AccessSerum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure
Background: This study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).Methods: This was a prospective cohort study. Three hundred and thirty-one consecutively enrolled AHF patients from March 2018 to November 2019 were divided into 3 subgroups according to sST2 levels: T1 (1.15–7.70 ng/ml; N = 110), T2 (7.71–17.24 ng/ml; N = 111), and T3 (17.26–47.42 ng/ml; N = 110). The patients were followed up for a median period of 21.0 months for the development of the primary endpoint. Cox proportional hazards model was performed to evaluate the prognostic value of sST2 for the clinical outcomes.Results: The mean age of patients was 69 years (range, 34–93 years), and 70.4% were male. During the follow-up period, 63 participants died. Patients with higher sST2 levels had lower left ventricular ejection fraction (correlation = −0.119, P = 0.031), and higher New York Heart Association classification (correlation = 0.443, P < 0.001) and N-terminal pro-B type natriuretic peptide (NT-proBNP) levels (correlation = 0.392, P < 0.001). Higher sST2 was also associated with creatinine, urea nitrogen, hemoglobin, and left ventricular mass index. Multivariate analysis revealed that sST2 (per log unit, hazard ratio: 2.174, 95% confidence interval [CI] 1.012–4.67, P = 0.047) and NT-proBNP (per log unit, HR 2.171, 95%CI 1.169–4.032, P < 0.001) were independent risk factors for the primary outcome in all patients with AHF.Conclusion: sST2 can provide prognostic information in AHF. The higher the sST2 level in patients with AHF, the higher the incidence of cardiovascular death.